ENDRA Life Sciences Inc Cash Flow-to-Debt Ratio
ENDRA Life Sciences Inc cash flow-to-debt ratio. ENDRA Life Sciences Inc (NDRA) has a Cash Flow-to-Debt Ratio of -0.57x as of June 2026, meaning its operating cash flow of $-927.56K could theoretically repay -1% of its total liabilities ($1.63 Million) in one year. Check how high is ENDRA Life Sciences Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ENDRA Life Sciences Inc (2014–2025)
Cash flow-to-debt ratio of ENDRA Life Sciences Inc from 2014 to 2025. Historical debt coverage capacity for ENDRA Life Sciences Inc across 12 annual periods. Check NDRA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ENDRA Life Sciences Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
ENDRA Life Sciences Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for ENDRA Life Sciences Inc. For the full cash flow conversion analysis, see ENDRA Life Sciences Inc (NDRA) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.25x | $-5.18 Million | $1.59 Million | ▲ +16.9% |
| 2024 | -3.91x | $-7.40 Million | $1.89 Million | ▲ +55.1% |
| 2023 | -8.72x | $-9.55 Million | $1.10 Million | ▼ -41.3% |
| 2022 | -6.17x | $-12.77 Million | $2.07 Million | ▼ -16.0% |
| 2021 | -5.32x | $-11.12 Million | $2.09 Million | ▲ +21.2% |
| 2020 | -6.75x | $-10.77 Million | $1.60 Million | ▼ -89.8% |
| 2019 | -3.56x | $-8.59 Million | $2.42 Million | ▲ +55.0% |
| 2018 | -7.90x | $-7.70 Million | $974.58K | ▼ -103.1% |
| 2017 | -3.89x | $-3.30 Million | $848.21K | ▼ -309.5% |
| 2016 | -0.95x | $-1.32 Million | $1.38 Million | ▲ +73.3% |
| 2015 | -3.56x | $-842.73K | $236.42K | ▲ +75.1% |
| 2014 | -14.32x | $-1.40 Million | $97.60K | — |